Clinical Trial Update: Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions [Phase 1]

View source ↗

Summary

Phase 1 bioavailability study of oxymorphone hydrochloride extended-release tablets (40 mg) under fed conditions, evaluating pharmacokinetics for a pain-managem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Oxymorphone hydrochloride extended-release tablets (oxymorphone hydrochloride)

Snippet

Sponsor: Sandoz | Conditions: Pain | Phase 1 | Status: COMPLETED